The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
News|Articles|December 7, 2014
Treating HIV-Associated Lymphoma
Author(s)Joseph Alvarnas, MD
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
Advertisement
Clinical Pearls
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
- The most appropriate way to treat patients with HIV and lymphoma has been a quandary for years.
- This study looked at autologous hematopoietic stem cell transplantation for the treatment of patients with chemotherapy-sensitive, relapsed/refractory HIV-associated lymphoma.
- Estimated probability of one-year OS was 86.6%.
<<<
Advertisement
Related to this article
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5